Radius Health Inc. (NASDAQ:RDUS) saw unusually-strong trading volume on Thursday . Approximately 1,791,855 shares traded hands during mid-day trading, an increase of 92% from the previous session’s volume of 932,480 shares.The stock last traded at $51.88 and had previously closed at $51.97.

Several analysts have commented on RDUS shares. Zacks Investment Research cut Radius Health from a “hold” rating to a “sell” rating in a report on Monday, May 9th. Cowen and Company started coverage on Radius Health in a report on Friday, May 6th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. restated a “buy” rating and issued a $70.00 price target on shares of Radius Health in a report on Friday, August 5th. Canaccord Genuity restated a “buy” rating on shares of Radius Health in a report on Tuesday, May 31st. Finally, HC Wainwright started coverage on Radius Health in a report on Monday, May 23rd. They issued a “buy” rating and a $55.00 price target for the company. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $63.66.

The company’s market cap is $2.22 billion. The company has a 50-day moving average of $43.38 and a 200-day moving average of $35.99.

Radius Health (NASDAQ:RDUS) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.95) by $0.06. During the same quarter last year, the firm earned ($0.61) earnings per share. On average, equities research analysts predict that Radius Health Inc. will post ($3.95) earnings per share for the current fiscal year.

Several large investors recently made changes to their positions in RDUS. Dimensional Fund Advisors LP bought a new stake in shares of Radius Health during the fourth quarter valued at approximately $1,362,000. Wells Fargo & Company MN raised its position in Radius Health by 7.5% in the fourth quarter. Wells Fargo & Company MN now owns 422,217 shares of the biopharmaceutical company’s stock valued at $25,984,000 after buying an additional 29,601 shares during the last quarter. Mutual of America Capital Management LLC raised its position in Radius Health by 18.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 36,483 shares of the biopharmaceutical company’s stock valued at $2,245,000 after buying an additional 5,683 shares during the last quarter. New York State Common Retirement Fund raised its position in Radius Health by 36.0% in the fourth quarter. New York State Common Retirement Fund now owns 69,048 shares of the biopharmaceutical company’s stock valued at $4,249,000 after buying an additional 18,259 shares during the last quarter. Finally, Swiss National Bank raised its position in Radius Health by 1.7% in the fourth quarter. Swiss National Bank now owns 36,100 shares of the biopharmaceutical company’s stock valued at $2,222,000 after buying an additional 600 shares during the last quarter.

Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.